Prevention of murine AIDS development by (R)-9-(2-phosphonylmethoxypropyl)adenine

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue 4, 1998, Pages 316-322

  Suruga, Yukio ^a,b   Makino, Masahiko ^a   Okada, Yoshiaki ^c   Tanaka, Hiromitsu ^b   De Clercq, Erik ^d   Baba, Masanori ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Murine AIDS; PMEA; PMPA; Reverse transcriptase inhibitor

Indexed keywords

RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; INFECTION PREVENTION; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; PRIORITY JOURNAL; RODENT DISEASE; VIRUS REPLICATION;

ANIMALIA; MURINAE; MURINE LEUKEMIA VIRUS; RODENTIA;

EID: 0032145456     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199808010-00002     Document Type: Article

References (35)

1. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-4.
2. St. Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557-9.
3. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
4. Jolicoeur P. Murine acquired immunodeficiency syndrome (MAIDS): an animal model to study the AIDS pathogenesis. FASEB J 1991;5:2398-405.
5. Morse HC III, Chattopadhyay SK, Makino M, et al. Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS 1992;6:607-21.
6. Aziz DG, Hanna Z, Jolicoeur P. Severe immunodeficiency disease induced by a defective murine leukemia virus. Nature 1989;338: 505-8.
7. Chattopadhyay SK, Morse HC III, Makino M, Ruscetti SK, Hartley JW. Defective virus is associated with induction of murine retrovirus-induced immunodeficiency syndrome. Proc Natl Acad Sci USA 1989;86:3862-6.
8. Cerny A, Hügin AW, Hardy RR, et al. B cells are required for induction of T cell abnormalities in a murine retrovirus-induced immunodeficiency syndrome. J Exp Med 1990;171:315-20.
9. Huang M, Simard C, Kay DG, Jolicoueur P. The majority of cells infected with the defective murine AIDS virus belong to the B-cell lineage. J Virol 1991;65:6562-71.
10. Kim WK, Tang Y, Kenny JJ, Longo DL, Morse HC III. In murine AIDS, B cells are early targets of defective virus and are required for efficient infection and expression of defective virus in T cells and macrophages. J Virol 1994;68:6767-9.
11. Gazzinelli RT, Giese NA, Morse HC III. In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS). J Exp Med 1994;180:2199-208.
12. Makino M, Yoshimatsu K, Azuma NI, et al. Rapid development of murine AIDS is dependent on signals provided by CD54 and CD11a. J Immunol 1995;155:974-81.
13. Mosier DE, Yetter RA, Morse HC III. Retroviral induction of acute lymphoproliferative disease and profound immunosuppression in adult C57BL/6 mice. J Exp Med 1985;161:766-84.
14. Gangemi JD, Cozens RM, De Clercq E, Balzarini J, Hochkeppel H-K. 9-(2-phosphonylmethoxyethyl) adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infection. Antimicrob Agents Chemother 1989; 33:1864-8.
15. Balzarini J, Naesens L, Herdewijn P, et al. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl) adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci USA 1989;86:332-6.
16. Tsai C-C, Fogis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 1995;270:1197-9.
17. Barditch-Crovo P, Toole J, Hendrix CW, et al. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis 1997; 176:406-13.
18. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997;5:129-42.
19. Rowe WP, Pugh WE, Hartley JW. Plaque assay techniques for murine leukemia viruses. Virology 1970;42:1136-9.
20. Pauwels R, De Clercq E, Desmyter J, et al. Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus. J Virol Methods 1987;16:171-85.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
22. Makino M, Morse HC III, Fredrickson TN, Hartley JW. H-2-associated and background genes influence the development of a murine retrovirus-induced immunodeficiency syndrome. J Immunol 1990;144:4347-55.
23. Okada Y, Suzuki K, Komuro K, Mizuochi T. High frequency of transmission of murine AIDS virus in C57BL/6 mice via mother's milk. J Virol 1992;66:5177-82.
24. + T cells lacking Thy-1 is expanded in a murine retrovirus-induced immunodeficiency syndrome, MAIDS. Eur J Immunol 1990;20:2783-87.
25. Basham T, Rios CD, Holdener T, Merigan TC. Zidovudine (AZT) reduced virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model. J Infect Dis 1990;161:1006-9.
26. Ohnota H, Okada Y, Ushijima H, Kitamura T, Komuro K, Mizuochi T. 3′-azido-3′-deoxythymidine prevents induction of murine acquired immunodeficiency syndrome in C57BL/10 mice infected with LP-BM5 murine leukemia viruses, a possible animal model for antiretroviral drug screening. Antimicrob Agents Chemother 1990;34:605-9.
27. Portnoi D, Stall AM, Schwartz D, Merigan TC, Herzenberg LA, Basham TY. Zidovudine (azido dideoxythymidine) inhibits characteristic early alteration of lymphoid cell populations in retrovirus-induced murine AIDS. J Immunol 1990;144:1705-10.
28. Bilello JA, Kort JJ, MacAuley C, Fredrickson TN, Yetter RA, Eiseman JL. ZDV delays but does not prevent the transmission of MAIDS by LP-BM5 MuLV-infected macrophage-monocytes. J Acquir Immune Defic Syndr 1992;5:571-6.
29. Fraternale A, Casablanca A, Rossi L, et al. Inhibition of murine AIDS by combination of AZT and dideoxycytidine 5′-triphosphate. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:164-73.
30. Harvie P, Omar RF, Dusserre N, et al. Antiviral efficacy and toxicity of ribavirin in murine acquired immunodeficiency syndrome model. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:451-61.
31. Palamara A, Garaci E, Rotilo G, et al. Inhibition of murine AIDS by reduced glutathione. AIDS Res Hum Retroviruses 1996;12: 1373-1381.
32. + T cells. J Virol 1994;68:5819-24.
33. Masuda A, Burton GF, Fuchs BA, et al. Follicular dendritic cell function and murine AIDS. Immunology 1994;81:41-6.
34. + T cells to the disorganization of lymphoid follicles in retrovirus-induced immunodeficiency syndrome, MAIDS. Clin Immunol Immunopathol 1996;81:253-60.
35. + T cells in resistance to murine AIDS in A/J mice. J Immunol 1992;149:1702-6.